0001384101-20-000033.txt : 20200303 0001384101-20-000033.hdr.sgml : 20200303 20200303175547 ACCESSION NUMBER: 0001384101-20-000033 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200228 FILED AS OF DATE: 20200303 DATE AS OF CHANGE: 20200303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kennedy Giulia C CENTRAL INDEX KEY: 0001769333 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36156 FILM NUMBER: 20684334 MAIL ADDRESS: STREET 1: 338 MAIN STREET #26E CITY: SAN FRANCISCO STATE: CA ZIP: 94105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERACYTE, INC. CENTRAL INDEX KEY: 0001384101 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 205455398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 243-6300 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: CALDEROME INC DATE OF NAME CHANGE: 20061219 4 1 wf-form4_158327613077235.xml FORM 4 X0306 4 2020-02-28 0 0001384101 VERACYTE, INC. VCYT 0001769333 Kennedy Giulia C 6000 SHORELINE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Scientific & Med Officer Common Stock 2020-02-28 4 A 0 12000 0 A 100018 D Common Stock 2020-03-02 4 F 0 896 0 D 99122 D Stock Option (right to buy) 24.69 2020-02-28 4 A 0 70000 0 A 2030-03-27 Common Stock 70000.0 70000 D Restricted stock units awarded on February 28, 2020 vest 25% on March 2, 2021 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. /s/ Keith Kennedy as attorney-in-fact 2020-03-03